Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PI 3-kinases: hidden potentials revealed.

Peter K Vogt1, Andreas G Bader, Sohye Kang

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. pkvogt@scripps.edu

Cell Cycle (Georgetown, Tex.)
|May 12, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The constitutive oncogenic and signaling activities of phosphatidylinositol 3-kinase (PI3K) isoforms p110β and p110δ.

bioRxiv : the preprint server for biology·2025
Same author

Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function.

Scientific reports·2025
Same author

Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2-Positive Solid Tumors.

Cancer immunology research·2024
Same author

Long Non-Coding RNAs as "MYC Facilitators".

Pathophysiology : the official journal of the International Society for Pathophysiology·2023
Same author

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field.

Journal of medicinal chemistry·2023
Same journal

Circular RNA circ_0001829 attenuates G2/M arrest to promote hepatocyte proliferation by sponging miR-3095-3p following liver injury.

Cell cycle (Georgetown, Tex.)·2026
Same journal

Identification of PGF+ endothelial cells associated with plaque instability in carotid atherosclerosis by scRNA-seq and RNA-seq analysis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

BMSCs-derived exosomal miR-196a-5p promotes macrophage M2 polarization and osteogenesis in postmenopausal osteoporosis through regulating Rspo2/Wnt/β-catenin signaling.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.

Cell cycle (Georgetown, Tex.)·2026
Same journal

OTUD5 promotes AML progression by stabilizing SLC7A11 to suppress ferroptosis.

Cell cycle (Georgetown, Tex.)·2026
Same journal

MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.

Cell cycle (Georgetown, Tex.)·2026
See all related articles

Phosphoinositide 3-kinases (PI 3-kinases) drive cancer through mutations or overexpression. PIK3CA mutations are oncogenic and targeted by inhibitors, while other PI 3-kinase isoforms warrant further investigation for their role in cancer.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Phosphoinositide 3-kinases (PI 3-kinases) are crucial signaling enzymes implicated in cell growth, proliferation, and survival.
  • Aberrant PI 3-kinase signaling is a hallmark of many human cancers, contributing to tumorigenesis and progression.

Purpose of the Study:

  • To elucidate the mechanisms by which PI 3-kinases contribute to oncogenesis.
  • To identify PI 3-kinase isoforms and their specific alterations as potential therapeutic targets in cancer treatment.

Main Methods:

  • Analysis of cancer-specific mutations in PIK3CA, the gene encoding the p110alpha catalytic subunit of PI 3-kinase.
  • Investigating the oncogenic transformation induced by overexpression of wild-type PI 3-kinase non-alpha isoforms (p110beta, gamma, and delta) in cell culture models.

Related Experiment Videos

Main Results:

  • Cancer-associated mutations in PIK3CA confer oncogenic activity in preclinical models.
  • These PIK3CA mutations are key drivers of the oncogenic cellular phenotype in human tumors.
  • Overexpression of wild-type p110beta, p110gamma, and p110delta isoforms induces oncogenic transformation in cell culture, suggesting a role beyond mutations.

Conclusions:

  • Mutations in PIK3CA are significant oncogenic drivers and promising targets for small molecule inhibitors.
  • While not found mutated in human cancer, deregulated expression of non-alpha PI 3-kinase isoforms may contribute to oncogenic properties and requires further research.